Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Arcellx, Inc. is a clinical-stage biotechnology company developing innovative cell therapies using its proprietary D-Domain platform to create safer, more effective, and broadly accessible CAR-T treatments. Its core products include ddCARs—single infusion CAR-T therapies—and ARC-SparX, a controllable universal CAR-T system. Targeting hematologic cancers, solid tumors, and autoimmune diseases, Arcellx leverages engineered synthetic binding domains to improve efficacy, safety, manufacturability, and treatment adaptability.
This description was generated via AI from an annual report. Updated about 1 year ago.